However, according to the bioinformatics analysis, among the three TAM RTKs, only TYRO3 is involved in anti-PD-1 resistance, while higher AXL or MERTK expression did not correlate with shorter survival times for melanoma patients who were treated with anti–PD-1. Here, AXL is linked to melanoma.